|
| |
| |
| Contents - Table des matières |
| Contents - Table des matières |
| Introduction |
Key issues in bladder cancer management
W. Kassouf |
| Review: Screening |
Screening for bladder cancer: the best opportunity to reduce mortality
Y. Fradet |
| Review: Chemoprevention |
Chemoprevention in bladder cancer: What’s new?
J.-B. Lattouf |
| Review: T1 High-grade bladder cancer |
The optimal management of T1 high-grade bladder cancer
K.G. Nepple, M.A. O’Donnell |
| Review: Urothelial bladder cancer |
Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer
V. Chalasani, J.I. Chin, J.I. Izawa |
| Review: BCG failure |
The management of BCG failure in non-muscle-invasive bladder cancer: an update
A.R. Zlotta, N.E. Fleshner, M.A. Jewett |
| Review: Role of lymphadenectomy |
Role of lymphadenectomy for invasive bladder cancer
F.A. Yafi, W. Kassouf |
| Review: Management of the urethra |
Management of the urethra in urothelial bladder cancer
A. Kanaroglou, B. Shayegan |
| Point/Counterpoint: Prostate-sparing cystectomy |
The case for prostate capsule-sparing radical cystectomy in selected patients
L. Klotz, J. Pinthus
Is sparing the prostate still considered radical cystectomy? The case against prostate-sparing cystectomy in selected patients
A. Kotb, A.G. Aprikian
|
| Review: Perioperative chemotherapy |
Perioperative chemotherapy for muscle-invasive bladder cancer
P. Black, A. So |
| Review: Metastatic urothelial cancer |
Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy
R.S. Svatek, A. Siefker-Radtke, C.P. Dinney |
| Review: Personalized medicine |
Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat
B. Ehdaie, S.C. Smith, D. Theodorescu |
| Review: Surveillance strategies |
Surveillance strategies after definitive therapy of invasive bladder cancer
I. Cagiannos, C. Morash |
